Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04496349 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
A Phase 2 study of Non-Hodgkin's Lymphoma and T-Prolymphocytic Leukemia, sponsored by Ascentage Pharma Group.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
- 1
- Study location
NCT04496349 is a Phase 2 study of Non-Hodgkin's Lymphoma and T-Prolymphocytic Leukemia that is actively recruiting participants, run by Ascentage Pharma Group. The registered enrollment target is 78 participants, below the 220-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04496349, a Phase 2 study of Non-Hodgkin's Lymphoma and T-Prolymphocytic Leukemia, is actively recruiting participants, sponsored by Ascentage Pharma Group.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.
Conditions Studied
Interventions
- DRUG APG-2575
- DRUG APG-115
Study Locations (1)
Texas
- MD Anderson - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2021-07-12 |
| Est. Completion | 2027-05-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04496349
The ClinicalTrials.gov registry entry for NCT04496349 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 220-participant average among 63 other Non-Hodgkin's Lymphoma trials with a reported enrollment target (65% lower). The listed sponsor is Ascentage Pharma Group, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Non-Hodgkin's Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which APG-2575 is the first listed.
NCT04496349 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT04496349 about?
NCT04496349 is a clinical study titled "A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL". The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.
What is the current status of trial NCT04496349?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2021-07-12. Estimated completion is 2027-05-31.
What conditions does trial NCT04496349 study?
This clinical trial studies the following conditions: Non-Hodgkin's Lymphoma, T-Prolymphocytic Leukemia.
What interventions are being tested in trial NCT04496349?
The interventions under investigation include: APG-2575 (DRUG), APG-115 (DRUG).
Who is sponsoring clinical trial NCT04496349?
This trial is sponsored by Ascentage Pharma Group, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04496349 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Hodgkin's Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cord Blood Transplant in Adults With Blood Cancers
RECRUITING · Phase 2
-
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
RECRUITING · Phase 2
-
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RECRUITING · Phase 2
-
Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas
ACTIVE NOT RECRUITING · Phase 2
-
Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.